The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending the approval of MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C virus (HCV) infection in adults and children aged 3 and older. This oral antiviral treatment, already approved for chronic HCV, showed a 96% cure rate in a Phase 3 study. Approval would allow earlier treatment of acute HCV, which is often asymptomatic, helping reduce transmission and liver complications. The final decision by the European Commission is expected in Q3 2026, potentially expanding MAVIRET's use to both acute and chronic HCV in the EU.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
